Publications by authors named "G A Islan"
Article Synopsis
- Gaucher Disease (GD) is a genetic condition caused by a deficiency in the enzyme glucocerebrosidase, and Velaglucerase alfa is used to replace this enzyme through therapy.
- Novel nanoparticle systems made from Eudragit have been developed to enhance the delivery and effectiveness of Velaglucerase alfa, demonstrating high stability and efficient encapsulation.
- In laboratory studies, these nanoparticles showed improved interaction with important proteins, better enzyme release in acidic conditions, and increased internalization in GD cells, leading to enhanced enzyme activity without affecting cell viability.
The objective of this study was to develop two lipid nanoparticle (LNP) formulations capable of efficiently expressing a reporter mRNA while co-delivering the anti-inflammatory drug dexamethasone (DX) to reduce inflammatory side effects in protein replacement therapies. Two types of LNPs were developed, in which 25% of cholesterol was replaced by DX. These LNPs contained either 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as a helper lipid.
View Article and Find Full Text PDFLipid nanoparticles (LNPs) tailored for mRNA delivery were optimized to serve as a platform for treating metabolic diseases. Four distinct lipid mixes (LMs) were formulated by modifying various components: LM1 (ALC-0315/DSPC/Cholesterol/ALC-0159), LM2 (ALC-0315/DOPE/Cholesterol/ALC-0159), LM3 (ALC-0315/DSPC/Cholesterol/DMG-PEG2k), and LM4 (DLin-MC3-DMA/DSPC/Cholesterol/ALC-0159). LNPs exhibited stability and homogeneity with a mean size of 75 to 90 nm, confirmed by cryo-TEM and SAXS studies.
View Article and Find Full Text PDFPlant and herbal essential oils (EOs) offer a wide range of pharmacological actions that include anticancer effects. Here, we evaluated the cytotoxic activity of EO from (chemotype linalool), (chemotype dihydrocarvone, LaDEO), (L.) (CnEO), , × , × , L.
View Article and Find Full Text PDFChagas disease is a neglected endemic disease prevalent in Latin American countries, affecting around 8 million people. The first-line treatment, benznidazole (BNZ), is effective in the acute stage of the disease but has limited efficacy in the chronic stage, possibly because current treatment regimens do not eradicate transiently dormant amastigotes. Nanostructured lipid carriers (NLC) appear to be a promising approach for delivering pharmaceutical active ingredients as they can have a positive impact on bioavailability by modifying the absorption, distribution, and elimination of the drug.
View Article and Find Full Text PDF